#METABOLOMICS WORKBENCH NuriaCG_20231027_025506 DATATRACK_ID:4422 STUDY_ID:ST002948 ANALYSIS_ID:AN004835 PROJECT_ID:PR001833
VERSION             	1
CREATED_ON             	October 30, 2023, 1:09 pm
#PROJECT
PR:PROJECT_TITLE                 	Targeted metabolomics in severe asthmatic patients treated with biologics.
PR:PROJECT_TYPE                  	Targeted MS analysis
PR:PROJECT_SUMMARY               	Severe asthmatic patients prescribed either Mepolizumab or Omalizumab were
PR:PROJECT_SUMMARY               	followed during treatment, and serum samples were collected before treatment
PR:PROJECT_SUMMARY               	(T0), and both at 6 (T1) and 18 months (T2) after starting biological treatment.
PR:PROJECT_SUMMARY               	Treatment monitoring was performed by the analysis of a set of inflammatory
PR:PROJECT_SUMMARY               	metabolites using targeted metabolomics.
PR:INSTITUTE                     	CEMBIO
PR:LAST_NAME                     	Contreras
PR:FIRST_NAME                    	Nuria
PR:ADDRESS                       	Urb. Montepríncipe s/n, Ctra. Boadilla del Monte km 5.3, Madrid 28668, Spain
PR:EMAIL                         	nuria.contrerasgomez1@ceu.es
PR:PHONE                         	+3491372470014750
#STUDY
ST:STUDY_TITLE                   	Multi-omics Approach Reveals a Specific Profile in Severe Asthmatic Patients
ST:STUDY_TITLE                   	Treated with Mepolizumab or Omalizumab
ST:STUDY_SUMMARY                 	The prevalence and severity of asthma continue to increase, and patients with
ST:STUDY_SUMMARY                 	uncontrolled severe asthma may require additional biological treatment. Given
ST:STUDY_SUMMARY                 	the pathophysiological heterogeneity underlying severe asthma, there is a lack
ST:STUDY_SUMMARY                 	of reliable biomarkers to monitor treatment response. In this context, this
ST:STUDY_SUMMARY                 	study aimed to identify potential biomarkers for monitoring the response to
ST:STUDY_SUMMARY                 	either Mepolizumab or Omalizumab in severe asthmatic patients using metabolomics
ST:STUDY_SUMMARY                 	and proteomics. Severe asthmatic patients who were prescribed either Mepolizumab
ST:STUDY_SUMMARY                 	(n=36) or Omalizumab (n=20) were followed during treatment, and serum samples
ST:STUDY_SUMMARY                 	were collected before treatment (T0), and both at 6 (T1) and 18 months (T2)
ST:STUDY_SUMMARY                 	after starting biological treatment. Treatment monitoring was performed by the
ST:STUDY_SUMMARY                 	analysis of a set of inflammatory metabolites and proteins using targeted
ST:STUDY_SUMMARY                 	metabolomic and proteomic approaches, along with the study of clinical variables
ST:STUDY_SUMMARY                 	such as the number of blood eosinophils, hospitalizations, and severe
ST:STUDY_SUMMARY                 	exacerbations. Mepolizumab and Omalizumab induced changes in the metabolomic and
ST:STUDY_SUMMARY                 	proteomic profiles of severe asthmatic patients. For both treatments, the
ST:STUDY_SUMMARY                 	greatest differences in metabolites were seen at T1 and maintained up to T2,
ST:STUDY_SUMMARY                 	whereas protein changes were seen throughout the treatment. Notable changes
ST:STUDY_SUMMARY                 	associated with anti-inflammatory effects included a decrease in several fatty
ST:STUDY_SUMMARY                 	acids, sphingosine-1-phosphate (S1P), L-arginine, and IL-10RA. Interestingly,
ST:STUDY_SUMMARY                 	S1P was the main feature that correlated significantly with eosinophilia in both
ST:STUDY_SUMMARY                 	treatments. These results unveil underlying molecular mechanisms that occur
ST:STUDY_SUMMARY                 	during Mepolizumab and Omalizumab treatments and provide potential biomarkers
ST:STUDY_SUMMARY                 	for monitoring treatment response in severe asthmatic patients.
ST:INSTITUTE                     	CEMBIO
ST:LAST_NAME                     	Contreras
ST:FIRST_NAME                    	Nuria
ST:ADDRESS                       	Urb. Montepríncipe s/n, Ctra. Boadilla del Monte km 5.3, Madrid 28668, Spain
ST:EMAIL                         	nuria.contrerasgomez1@ceu.es
ST:PHONE                         	+3491372470014750
ST:NUM_GROUPS                    	2
ST:TOTAL_SUBJECTS                	54
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:AGE_OR_AGE_RANGE              	≥ 18 years
SU:GENDER                        	Male and female
SU:HUMAN_MEDICATIONS             	Mepolizumab or Omalizumab
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	O1	O-T0-01	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-01.mzML
SUBJECT_SAMPLE_FACTORS           	O1	O-T1-01	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-01.mzML
SUBJECT_SAMPLE_FACTORS           	O1	O-T2-01	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-01.mzML
SUBJECT_SAMPLE_FACTORS           	O2	O-T0-02	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-02.mzML
SUBJECT_SAMPLE_FACTORS           	O2	O-T1-02	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-02.mzML
SUBJECT_SAMPLE_FACTORS           	O2	O-T2-02	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-02.mzML
SUBJECT_SAMPLE_FACTORS           	O3	O-T0-03	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-03.mzML
SUBJECT_SAMPLE_FACTORS           	O3	O-T1-03	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-03.mzML
SUBJECT_SAMPLE_FACTORS           	O3	O-T2-03	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-03.mzML
SUBJECT_SAMPLE_FACTORS           	O4	O-T0-04	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-04.mzML
SUBJECT_SAMPLE_FACTORS           	O4	O-T1-04	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-04.mzML
SUBJECT_SAMPLE_FACTORS           	O4	O-T2-04	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-04.mzML
SUBJECT_SAMPLE_FACTORS           	O5	O-T0-05	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-05.mzML
SUBJECT_SAMPLE_FACTORS           	O5	O-T1-05	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-05.mzML
SUBJECT_SAMPLE_FACTORS           	O5	O-T2-05	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-05.mzML
SUBJECT_SAMPLE_FACTORS           	O6	O-T0-06	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-06.mzML
SUBJECT_SAMPLE_FACTORS           	O6	O-T1-06	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-06.mzML
SUBJECT_SAMPLE_FACTORS           	O6	O-T2-06	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-06.mzML
SUBJECT_SAMPLE_FACTORS           	O7	O-T0-08	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-08.mzML
SUBJECT_SAMPLE_FACTORS           	O7	O-T1-08	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-08.mzML
SUBJECT_SAMPLE_FACTORS           	O7	O-T2-08	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-08.mzML
SUBJECT_SAMPLE_FACTORS           	O8	O-T0-09	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-09.mzML
SUBJECT_SAMPLE_FACTORS           	O8	O-T1-09	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-09.mzML
SUBJECT_SAMPLE_FACTORS           	O8	O-T2-09	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-09.mzML
SUBJECT_SAMPLE_FACTORS           	O9	O-T0-10	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-10.mzML
SUBJECT_SAMPLE_FACTORS           	O9	O-T1-10	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-10.mzML
SUBJECT_SAMPLE_FACTORS           	O9	O-T2-10	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-10.mzML
SUBJECT_SAMPLE_FACTORS           	O10	O-T0-12	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-12.mzML
SUBJECT_SAMPLE_FACTORS           	O10	O-T1-12	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-12.mzML
SUBJECT_SAMPLE_FACTORS           	O10	O-T2-12	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-12.mzML
SUBJECT_SAMPLE_FACTORS           	O11	O-T0-13	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-13.mzML
SUBJECT_SAMPLE_FACTORS           	O11	O-T1-13	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-13.mzML
SUBJECT_SAMPLE_FACTORS           	O11	O-T2-13	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-13.mzML
SUBJECT_SAMPLE_FACTORS           	O12	O-T0-14	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-14.mzML
SUBJECT_SAMPLE_FACTORS           	O12	O-T1-14	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-14.mzML
SUBJECT_SAMPLE_FACTORS           	O12	O-T2-14	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-14.mzML
SUBJECT_SAMPLE_FACTORS           	O13	O-T0-16	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-16.mzML
SUBJECT_SAMPLE_FACTORS           	O13	O-T1-16	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-16.mzML
SUBJECT_SAMPLE_FACTORS           	O13	O-T2-16	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-16.mzML
SUBJECT_SAMPLE_FACTORS           	O14	O-T0-17	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-17.mzML
SUBJECT_SAMPLE_FACTORS           	O14	O-T1-17	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-17.mzML
SUBJECT_SAMPLE_FACTORS           	O14	O-T2-17	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-17.mzML
SUBJECT_SAMPLE_FACTORS           	O15	O-T0-18	Time:T0 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T0-18.mzML
SUBJECT_SAMPLE_FACTORS           	O15	O-T1-18	Time:T1 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T1-18.mzML
SUBJECT_SAMPLE_FACTORS           	O15	O-T2-18	Time:T2 | Treatment:Omalizumab	Gender=M; RAW_FILE_NAME=O-T2-18.mzML
SUBJECT_SAMPLE_FACTORS           	O16	O-T0-20	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-20.mzML
SUBJECT_SAMPLE_FACTORS           	O16	O-T1-20	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-20.mzML
SUBJECT_SAMPLE_FACTORS           	O16	O-T2-20	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-20.mzML
SUBJECT_SAMPLE_FACTORS           	O17	O-T0-22	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-22.mzML
SUBJECT_SAMPLE_FACTORS           	O17	O-T1-22	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-22.mzML
SUBJECT_SAMPLE_FACTORS           	O17	O-T2-22	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-22.mzML
SUBJECT_SAMPLE_FACTORS           	O18	O-T0-23	Time:T0 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T0-23.mzML
SUBJECT_SAMPLE_FACTORS           	O18	O-T1-23	Time:T1 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T1-23.mzML
SUBJECT_SAMPLE_FACTORS           	O18	O-T2-23	Time:T2 | Treatment:Omalizumab	Gender=F; RAW_FILE_NAME=O-T2-23.mzML
SUBJECT_SAMPLE_FACTORS           	Me1	Me-T0-01	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-01.mzML
SUBJECT_SAMPLE_FACTORS           	Me1	Me-T1-01	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-01.mzML
SUBJECT_SAMPLE_FACTORS           	Me1	Me-T2-01	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-01.mzML
SUBJECT_SAMPLE_FACTORS           	Me2	Me-T0-03	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-03.mzML
SUBJECT_SAMPLE_FACTORS           	Me2	Me-T1-03	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-03.mzML
SUBJECT_SAMPLE_FACTORS           	Me2	Me-T2-03	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-03.mzML
SUBJECT_SAMPLE_FACTORS           	Me3	Me-T0-04	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-04.mzML
SUBJECT_SAMPLE_FACTORS           	Me3	Me-T1-04	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-04.mzML
SUBJECT_SAMPLE_FACTORS           	Me3	Me-T2-04	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-04.mzML
SUBJECT_SAMPLE_FACTORS           	Me4	Me-T0-05	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-05.mzML
SUBJECT_SAMPLE_FACTORS           	Me4	Me-T1-05	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-05.mzML
SUBJECT_SAMPLE_FACTORS           	Me4	Me-T2-05	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-05.mzML
SUBJECT_SAMPLE_FACTORS           	Me5	Me-T0-06	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-06.mzML
SUBJECT_SAMPLE_FACTORS           	Me5	Me-T1-06	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-06.mzML
SUBJECT_SAMPLE_FACTORS           	Me5	Me-T2-06	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-06.mzML
SUBJECT_SAMPLE_FACTORS           	Me6	Me-T0-07	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-07.mzML
SUBJECT_SAMPLE_FACTORS           	Me6	Me-T1-07	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-07.mzML
SUBJECT_SAMPLE_FACTORS           	Me6	Me-T2-07	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-07.mzML
SUBJECT_SAMPLE_FACTORS           	Me7	Me-T0-08	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-08.mzML
SUBJECT_SAMPLE_FACTORS           	Me7	Me-T1-08	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-08.mzML
SUBJECT_SAMPLE_FACTORS           	Me7	Me-T2-08	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-08.mzML
SUBJECT_SAMPLE_FACTORS           	Me8	Me-T0-10	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-10.mzML
SUBJECT_SAMPLE_FACTORS           	Me8	Me-T1-10	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-10.mzML
SUBJECT_SAMPLE_FACTORS           	Me8	Me-T2-10	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-10.mzML
SUBJECT_SAMPLE_FACTORS           	Me9	Me-T0-11	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-11.mzML
SUBJECT_SAMPLE_FACTORS           	Me9	Me-T1-11	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-11.mzML
SUBJECT_SAMPLE_FACTORS           	Me9	Me-T2-11	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-11.mzML
SUBJECT_SAMPLE_FACTORS           	Me10	Me-T0-12	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-12.mzML
SUBJECT_SAMPLE_FACTORS           	Me10	Me-T1-12	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-12.mzML
SUBJECT_SAMPLE_FACTORS           	Me10	Me-T2-12	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-12.mzML
SUBJECT_SAMPLE_FACTORS           	Me11	Me-T0-16	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-16.mzML
SUBJECT_SAMPLE_FACTORS           	Me11	Me-T1-16	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-16.mzML
SUBJECT_SAMPLE_FACTORS           	Me11	Me-T2-16	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-16.mzML
SUBJECT_SAMPLE_FACTORS           	Me12	Me-T0-17	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-17.mzML
SUBJECT_SAMPLE_FACTORS           	Me12	Me-T1-17	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-17.mzML
SUBJECT_SAMPLE_FACTORS           	Me12	Me-T2-17	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-17.mzML
SUBJECT_SAMPLE_FACTORS           	Me13	Me-T0-18	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-18.mzML
SUBJECT_SAMPLE_FACTORS           	Me13	Me-T1-18	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-18.mzML
SUBJECT_SAMPLE_FACTORS           	Me13	Me-T2-18	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-18.mzML
SUBJECT_SAMPLE_FACTORS           	Me14	Me-T0-19	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-19.mzML
SUBJECT_SAMPLE_FACTORS           	Me14	Me-T1-19	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-19.mzML
SUBJECT_SAMPLE_FACTORS           	Me14	Me-T2-19	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-19.mzML
SUBJECT_SAMPLE_FACTORS           	Me15	Me-T0-20	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-20.mzML
SUBJECT_SAMPLE_FACTORS           	Me15	Me-T1-20	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-20.mzML
SUBJECT_SAMPLE_FACTORS           	Me15	Me-T2-20	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-20.mzML
SUBJECT_SAMPLE_FACTORS           	Me16	Me-T0-21	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-21.mzML
SUBJECT_SAMPLE_FACTORS           	Me16	Me-T1-21	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-21.mzML
SUBJECT_SAMPLE_FACTORS           	Me16	Me-T2-21	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-21.mzML
SUBJECT_SAMPLE_FACTORS           	Me17	Me-T0-22	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-22.mzML
SUBJECT_SAMPLE_FACTORS           	Me17	Me-T1-22	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-22.mzML
SUBJECT_SAMPLE_FACTORS           	Me17	Me-T2-22	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-22.mzML
SUBJECT_SAMPLE_FACTORS           	Me18	Me-T0-23	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-23.mzML
SUBJECT_SAMPLE_FACTORS           	Me18	Me-T1-23	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-23.mzML
SUBJECT_SAMPLE_FACTORS           	Me18	Me-T2-23	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-23.mzML
SUBJECT_SAMPLE_FACTORS           	Me19	Me-T0-25	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-25.mzML
SUBJECT_SAMPLE_FACTORS           	Me19	Me-T1-25	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-25.mzML
SUBJECT_SAMPLE_FACTORS           	Me19	Me-T2-25	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-25.mzML
SUBJECT_SAMPLE_FACTORS           	Me20	Me-T0-26	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-26.mzML
SUBJECT_SAMPLE_FACTORS           	Me20	Me-T1-26	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-26.mzML
SUBJECT_SAMPLE_FACTORS           	Me20	Me-T2-26	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-26.mzML
SUBJECT_SAMPLE_FACTORS           	Me21	Me-T0-27	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-27.mzML
SUBJECT_SAMPLE_FACTORS           	Me21	Me-T1-27	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-27.mzML
SUBJECT_SAMPLE_FACTORS           	Me21	Me-T2-27	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-27.mzML
SUBJECT_SAMPLE_FACTORS           	Me22	Me-T0-29	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-29.mzML
SUBJECT_SAMPLE_FACTORS           	Me22	Me-T1-29	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-29.mzML
SUBJECT_SAMPLE_FACTORS           	Me22	Me-T2-29	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-29.mzML
SUBJECT_SAMPLE_FACTORS           	Me23	Me-T0-30	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-30.mzML
SUBJECT_SAMPLE_FACTORS           	Me23	Me-T1-30	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-30.mzML
SUBJECT_SAMPLE_FACTORS           	Me23	Me-T2-30	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-30.mzML
SUBJECT_SAMPLE_FACTORS           	Me24	Me-T0-31	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-31.mzML
SUBJECT_SAMPLE_FACTORS           	Me24	Me-T1-31	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-31.mzML
SUBJECT_SAMPLE_FACTORS           	Me24	Me-T2-31	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-31.mzML
SUBJECT_SAMPLE_FACTORS           	Me25	Me-T0-32	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-32.mzML
SUBJECT_SAMPLE_FACTORS           	Me25	Me-T1-32	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-32.mzML
SUBJECT_SAMPLE_FACTORS           	Me25	Me-T2-32	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-32.mzML
SUBJECT_SAMPLE_FACTORS           	Me26	Me-T0-33	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-33.mzML
SUBJECT_SAMPLE_FACTORS           	Me26	Me-T1-33	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-33.mzML
SUBJECT_SAMPLE_FACTORS           	Me26	Me-T2-33	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-33.mzML
SUBJECT_SAMPLE_FACTORS           	Me27	Me-T0-34	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-34.mzML
SUBJECT_SAMPLE_FACTORS           	Me27	Me-T1-34	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-34.mzML
SUBJECT_SAMPLE_FACTORS           	Me27	Me-T2-34	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-34.mzML
SUBJECT_SAMPLE_FACTORS           	Me28	Me-T0-35	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-35.mzML
SUBJECT_SAMPLE_FACTORS           	Me28	Me-T1-35	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-35.mzML
SUBJECT_SAMPLE_FACTORS           	Me28	Me-T2-35	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-35.mzML
SUBJECT_SAMPLE_FACTORS           	Me29	Me-T0-37	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-37.mzML
SUBJECT_SAMPLE_FACTORS           	Me29	Me-T1-37	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-37.mzML
SUBJECT_SAMPLE_FACTORS           	Me29	Me-T2-37	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-37.mzML
SUBJECT_SAMPLE_FACTORS           	Me30	Me-T0-38	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-38.mzML
SUBJECT_SAMPLE_FACTORS           	Me30	Me-T1-38	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-38.mzML
SUBJECT_SAMPLE_FACTORS           	Me30	Me-T2-38	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-38.mzML
SUBJECT_SAMPLE_FACTORS           	Me31	Me-T0-39	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-39.mzML
SUBJECT_SAMPLE_FACTORS           	Me31	Me-T1-39	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-39.mzML
SUBJECT_SAMPLE_FACTORS           	Me31	Me-T2-39	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-39.mzML
SUBJECT_SAMPLE_FACTORS           	Me32	Me-T0-40	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-40.mzML
SUBJECT_SAMPLE_FACTORS           	Me32	Me-T1-40	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-40.mzML
SUBJECT_SAMPLE_FACTORS           	Me32	Me-T2-40	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-40.mzML
SUBJECT_SAMPLE_FACTORS           	Me33	Me-T0-41	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-41.mzML
SUBJECT_SAMPLE_FACTORS           	Me33	Me-T1-41	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-41.mzML
SUBJECT_SAMPLE_FACTORS           	Me33	Me-T2-41	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-41.mzML
SUBJECT_SAMPLE_FACTORS           	Me34	Me-T0-42	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-42.mzML
SUBJECT_SAMPLE_FACTORS           	Me34	Me-T1-42	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-42.mzML
SUBJECT_SAMPLE_FACTORS           	Me34	Me-T2-42	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-42.mzML
SUBJECT_SAMPLE_FACTORS           	Me35	Me-T0-43	Time:T0 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T0-43.mzML
SUBJECT_SAMPLE_FACTORS           	Me35	Me-T1-43	Time:T1 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T1-43.mzML
SUBJECT_SAMPLE_FACTORS           	Me35	Me-T2-43	Time:T2 | Treatment:Mepolizumab	Gender=M; RAW_FILE_NAME=Me-T2-43.mzML
SUBJECT_SAMPLE_FACTORS           	Me36	Me-T0-45	Time:T0 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T0-45.mzML
SUBJECT_SAMPLE_FACTORS           	Me36	Me-T1-45	Time:T1 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T1-45.mzML
SUBJECT_SAMPLE_FACTORS           	Me36	Me-T2-45	Time:T2 | Treatment:Mepolizumab	Gender=F; RAW_FILE_NAME=Me-T2-45.mzML
#COLLECTION
CO:COLLECTION_SUMMARY            	Whole blood from the three hospital-scheduled visits was incubated with a
CO:COLLECTION_SUMMARY            	clotting agent in Vacutainer SST II tubes. Samples were placed at room
CO:COLLECTION_SUMMARY            	temperature for 30 min and then centrifuged at 2000 x g for 10 min for serum
CO:COLLECTION_SUMMARY            	recovery. Serum samples were stored at -80ºC until further metabolomic
CO:COLLECTION_SUMMARY            	analyses.
CO:SAMPLE_TYPE                   	Blood (serum)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	Patients were prescribed add-on biological treatments following the GINA
TR:TREATMENT_SUMMARY             	guidelines. Mepolizumab was used in patients with >300 eosinophils/µL (without
TR:TREATMENT_SUMMARY             	corticosteroids treatment) or >100 eosinophils/µL (with corticosteroids).
TR:TREATMENT_SUMMARY             	Meanwhile, Omalizumab was chosen in uncontrolled severe allergic asthmatics with
TR:TREATMENT_SUMMARY             	serum IgE levels between 30 and 1500 IU/mL and body weight within the dosing
TR:TREATMENT_SUMMARY             	range.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	For sample preparation, 50 µL of serum was mixed with 150 µL of cold (−20
SP:SAMPLEPREP_SUMMARY            	°C) methanol: ethanol mix (MeOH:EtOH) (1:1). Then, serum samples were
SP:SAMPLEPREP_SUMMARY            	vortex-mixed for 1 min, placed on ice for 15 min and centrifuged at 16000× g
SP:SAMPLEPREP_SUMMARY            	for 20 min at 4 °C. Subsequently, 70 µL of the supernatant was transferred
SP:SAMPLEPREP_SUMMARY            	into an LC vial and mixed with 50 µL of ISTD mix, (with a final concentration
SP:SAMPLEPREP_SUMMARY            	of 0.2 µg/mL for HILIC and 0.3 µg/mL for re-versed-phase method) and 440 µL
SP:SAMPLEPREP_SUMMARY            	of the initial conditions of the mobile phases for the HILIC method. For blank
SP:SAMPLEPREP_SUMMARY            	preparation, 50 µL of water was used and the same steps as described above were
SP:SAMPLEPREP_SUMMARY            	followed.
SP:EXTRACT_STORAGE               	-20℃
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	To detect metabolites with medium polarity (arachidonic acid, bilirubin, lactic
CH:CHROMATOGRAPHY_SUMMARY        	acid, lauric acid, LPC 14:0, LPC 16:0, LPC 17:0, LPC 17:1, LPC 18:0, LPC 18:1,
CH:CHROMATOGRAPHY_SUMMARY        	LPC 18:1 d7, LPC 19:0, LPC 20:0, LPE 18:0, LPI 20:4, oleic acid, palmitic acid
CH:CHROMATOGRAPHY_SUMMARY        	d31, palmitoleic acid, sphingosine, sphingosine d7, and S1P). For metabolite
CH:CHROMATOGRAPHY_SUMMARY        	separation, a gradient elution on a Supelco Ascentis Express reversed-phase (150
CH:CHROMATOGRAPHY_SUMMARY        	mm × 2.1 mm × 2.7 μm) column maintained at 60 °C was used. The mobile phases
CH:CHROMATOGRAPHY_SUMMARY        	consisted of (A) water, and (B) ACN, both with 0.1% acetic acid, obtaining a
CH:CHROMATOGRAPHY_SUMMARY        	final pH of 3.3 in the aqueous phase. The flow rate was 0.6 mL/min. The gradient
CH:CHROMATOGRAPHY_SUMMARY        	started with 20% of B for 2 min, then increased up to 100% until 10 min and
CH:CHROMATOGRAPHY_SUMMARY        	maintained for 5 min, then returned to initial conditions until 20 min.
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 1260 Infinity II
CH:COLUMN_NAME                   	Merck Supelco Ascentis Express C8 (150 x 2.1mm, 2.7um, 90Å)
CH:SOLVENT_A                     	100% water; 0.1% acetic acid
CH:SOLVENT_B                     	100% acetonitrile; 0.1% acetic acid
CH:FLOW_GRADIENT                 	The gradient started with 20% of B for 2 min, then increased up to 100% until 10
CH:FLOW_GRADIENT                 	min and maintained for 5 min, then returned to initial conditions until 20 min.
CH:FLOW_RATE                     	0.6mL/min
CH:COLUMN_TEMPERATURE            	60ºC
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6470 QQQ
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	UNSPECIFIED
MS:MS_COMMENTS                   	The MS was done with polarity switching with the following conditions: 3500 V of
MS:MS_COMMENTS                   	capillary voltage in positive ESI mode and 3000V in negative ESI mode, a
MS:MS_COMMENTS                   	nebulizer gas flow rate of 10.0 L/min, a source temperature of 250 °C; and a
MS:MS_COMMENTS                   	source pressure of 45 psi. Chromatogram visualization and peak areas were
MS:MS_COMMENTS                   	obtained using MassHunter Workstation B.05.00 and MassHunter QQQ Quantitative
MS:MS_COMMENTS                   	Analysis B.08.00, respectively.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Areas
MS_METABOLITE_DATA_START
Samples	O-T0-01	O-T1-01	O-T2-01	O-T0-02	O-T1-02	O-T2-02	O-T0-03	O-T1-03	O-T2-03	O-T0-04	O-T1-04	O-T2-04	O-T0-05	O-T1-05	O-T2-05	O-T0-06	O-T1-06	O-T2-06	O-T0-08	O-T1-08	O-T2-08	O-T0-09	O-T1-09	O-T2-09	O-T0-10	O-T1-10	O-T2-10	O-T0-12	O-T1-12	O-T2-12	O-T0-13	O-T1-13	O-T2-13	O-T0-14	O-T1-14	O-T2-14	O-T0-16	O-T1-16	O-T2-16	O-T0-17	O-T1-17	O-T2-17	O-T0-18	O-T1-18	O-T2-18	O-T0-20	O-T1-20	O-T2-20	O-T0-22	O-T1-22	O-T2-22	O-T0-23	O-T1-23	O-T2-23	Me-T0-01	Me-T1-01	Me-T2-01	Me-T0-03	Me-T1-03	Me-T2-03	Me-T0-04	Me-T1-04	Me-T2-04	Me-T0-05	Me-T1-05	Me-T2-05	Me-T0-06	Me-T1-06	Me-T2-06	Me-T0-07	Me-T1-07	Me-T2-07	Me-T0-08	Me-T1-08	Me-T2-08	Me-T0-10	Me-T1-10	Me-T2-10	Me-T0-11	Me-T1-11	Me-T2-11	Me-T0-12	Me-T1-12	Me-T2-12	Me-T0-16	Me-T1-16	Me-T2-16	Me-T0-17	Me-T1-17	Me-T2-17	Me-T0-18	Me-T1-18	Me-T2-18	Me-T0-19	Me-T1-19	Me-T2-19	Me-T0-20	Me-T1-20	Me-T2-20	Me-T0-21	Me-T1-21	Me-T2-21	Me-T0-22	Me-T1-22	Me-T2-22	Me-T0-23	Me-T1-23	Me-T2-23	Me-T0-25	Me-T1-25	Me-T2-25	Me-T0-26	Me-T1-26	Me-T2-26	Me-T0-27	Me-T1-27	Me-T2-27	Me-T0-29	Me-T1-29	Me-T2-29	Me-T0-30	Me-T1-30	Me-T2-30	Me-T0-31	Me-T1-31	Me-T2-31	Me-T0-32	Me-T1-32	Me-T2-32	Me-T0-33	Me-T1-33	Me-T2-33	Me-T0-34	Me-T1-34	Me-T2-34	Me-T0-35	Me-T1-35	Me-T2-35	Me-T0-37	Me-T1-37	Me-T2-37	Me-T0-38	Me-T1-38	Me-T2-38	Me-T0-39	Me-T1-39	Me-T2-39	Me-T0-40	Me-T1-40	Me-T2-40	Me-T0-41	Me-T1-41	Me-T2-41	Me-T0-42	Me-T1-42	Me-T2-42	Me-T0-43	Me-T1-43	Me-T2-43	Me-T0-45	Me-T1-45	Me-T2-45
Factors	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Omalizumab	Time:T1 | Treatment:Omalizumab	Time:T2 | Treatment:Omalizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab	Time:T0 | Treatment:Mepolizumab	Time:T1 | Treatment:Mepolizumab	Time:T2 | Treatment:Mepolizumab
Sphingosine	1093045375	2075275375	1028375	208375	107375	61598375	61375	202375	182375	210375	150375	249375	296375	257375	234375	146375	138375	132375	643375	585375	269375	236375	385375	406375	64375	290375	108375	111509375	235398375	479978375	261375	167375	158375	-11625	42375	290375	249375	298375	124375	955375	359375	375375	317375	208375	65697375	534375	698375	162375	531375	399375	61375	119375	140375	141375	187375	303375	247375	122738375	262065375	539620375	392375	256375	387375	179375	152375	73375	518375	16375	184375	116395375	245415375	509571375	345375	277375	146375	270375	294375	113375	688375	-13625	279375	153375	335375	45375	107375	41375	58645375	153375	487375	88375	365375	155375	451375	160375	131375	2098375	1811636375	978375	416375	32375	56375	90375	12375	79375	107375	24375	61375	312375	203375	608375	103375	386375	210375	1094375	198375	66375	26375	219757375	442947375	945964375	600375	52375	1361375	196375	147375	206375	121375	671375	262375	64375	155375	-84625	51375	74375	164375	231375	266375	212375	158375	153375	44375	466375	3375	79375	200375	89375	212375	1029005375	1974525375	1051375	-276625	113375	159375	177375	128375	173375	322375	72375	607375	152375	35375	86375
Sphingosine-1-Phosphate	3327375	5523375	1469375	1549375	869375	893375	3622375	3071375	3290375	1891375	1417375	1386375	2384375	2751375	2614375	1600375	2876375	3177375	1372375	1811375	1775375	2636375	2832375	3486375	1996375	1644375	2350375	1016375	1338375	1579375	832375	1669375	1654375	1549375	1239375	2432375	1518375	1312375	1776375	2582375	1302375	1134375	4374375	886375	974375	3169375	2552375	2789375	2092375	2941375	2126375	2186375	2055375	1746375	1644375	1524375	1363375	1195375	1341375	1716375	3621375	2840375	4047375	2602375	2262375	2453375	2565375	1199375	1774375	1149375	741375	2024375	3480375	2831375	1750375	3288375	1836375	1567375	3406375	1218375	1585375	3987375	4215375	1754375	1936375	819375	1057375	1417375	2523375	1411375	3555375	3730375	2787375	3034375	1427375	4806375	5332375	1507375	2612375	1337375	1844375	2174375	2506375	1313375	2794375	2109375	1864375	3026375	1709375	2464375	1786375	2820375	3275375	4601375	1182375	638375	2028375	1226375	1661375	3095375	3682375	1742375	3511375	3369375	3014375	3458375	2209375	3650375	2914375	2507375	2170375	1469375	2508375	2457375	3215375	1586375	1440375	802375	2779375	3237375	1763375	3063375	2539375	3587375	1611375	1453375	2214375	3030375	5422375	1860375	-19625	1692375	1823375	2585375	1909375	1834375	2212375	2383375	3041375	1946375	1785375	1705375
LPC 14:0	56587625	101901625	17399625	21732625	10794625	13639625	21743625	23862625	25561625	13430625	13519625	13906625	19603625	13784625	15480625	27968625	24849625	7842625	9486625	14108625	24931625	14230625	14100625	35053625	18786625	19167625	24487625	14812625	19537625	29066625	11411625	17028625	9623625	25466625	19481625	23994625	36655625	8383625	10058625	20809625	15736625	16130625	15804625	11711625	14118625	19777625	8463625	11515625	7677625	6851625	24441625	27900625	22131625	19127625	28460625	15887625	24267625	16298625	21837625	32554625	21103625	4043625	19857625	13222625	12871625	39811625	28569625	15711625	24102625	15347625	20638625	30876625	24613625	20462625	12062625	19634625	16694625	24759625	10804625	13321625	9028625	19753625	34347625	17062625	29961625	10473625	12927625	10043625	9408625	12799625	10221625	24225625	16144625	4417625	7730625	19593625	87437625	15638625	18860625	15176625	13422625	15588625	18481625	9003625	9871625	8586625	7821625	5516625	10429625	20204625	10198625	22425625	33006625	24665625	7602625	7020625	22355625	16830625	25726625	47152625	14084625	11874625	27825625	14465625	18934625	16607625	11239625	6825625	15720625	20749625	20457625	4662625	12019625	16817625	7151625	14832625	14545625	8977625	19567625	17187625	8826625	22537625	17615625	19738625	22420625	6666625	14523625	52250625	95998625	16835625	-62375	13720625	13537625	17522625	15163625	11604625	29808625	18411625	23437625	18566625	20417625	23857625
LPC 16:0	325380525	530671225	104800025	106259125	68489425	83816325	113666725	98916725	143093725	85811625	86426925	86883325	133484225	82777925	100318125	119336425	116468125	84187925	67868725	101793425	120601825	113871025	116271825	146152225	105112125	106870725	123478925	91047925	118474525	178306125	76885725	92418725	80268325	84837025	97948425	112110925	134742625	156550225	86933625	101966625	87185225	88829625	134719225	72126025	89638625	116162025	103201025	68206425	91177125	90600025	95415625	126862625	103143125	129374125	114431525	94737025	116815525	99993625	133503525	198385825	131901125	88569225	149855025	74815225	71342825	150093125	155790425	96313225	116470325	94422625	124759725	186864325	138432725	129526225	135259225	111022925	156645325	132304725	79736325	79528025	81335525	124364525	148517125	128241025	149090925	65561625	79458625	65782225	87297525	93784525	103492225	150141325	97079325	55862825	58211625	123893125	492244325	93284725	101595025	128827425	109915025	139157825	109014725	94776625	84208225	86342325	84816125	69813125	79064725	86457025	75654125	99975925	119027625	131356425	77253825	75067025	102534725	109001625	163453925	287372725	120133225	92232725	128800125	88305625	98491525	86652125	81807325	73720925	86924425	161032425	124568925	77975925	84481125	118458925	86710325	89110025	88842825	58291425	88603225	84626925	71734925	121325825	100894025	98404725	85478425	65315225	101907325	310591425	516358825	101381125	-217775	84930425	85760425	126195725	108757625	64965125	132892925	78405425	119827825	102819525	78401525	107629325
LPC 17:0	473585	802325	139695	174595	93865	121015	145985	89815	197285	112325	114925	114375	212975	140845	154905	165305	168335	132295	94375	127115	165765	138745	109315	232565	87635	106405	173585	126205	157235	241385	126085	126515	112135	124195	131785	160575	162645	264595	120065	112505	104025	93415	155905	100245	118285	132485	82925	109685	98965	86295	122595	194865	139945	154515	134195	108575	127235	139505	189145	274325	150805	84995	179995	110865	123335	264605	112005	71175	86435	130755	175815	259565	195895	217375	294565	144365	261325	244795	151005	137405	149505	208125	233165	201735	277035	86485	114335	103805	78285	100005	146715	217085	123445	67775	98955	100155	745525	128155	134755	191535	135925	204965	152305	133925	122935	91495	109445	83235	83785	122855	101605	132825	238285	146155	81835	88315	100225	159325	244035	424755	176595	115405	134695	104125	115535	75925	99945	82935	109675	210985	197925	88425	99945	122875	95765	110235	121525	93965	90935	90235	80495	279195	158815	98805	129995	70435	149865	443535	798865	140345	-915	111575	111405	188835	133705	81455	171235	146255	174515	119245	143805	194355
LPC 17:1	9018	15784	2710	2671	1870	2186	2638	2783	3242	2236	2448	2254	3549	2398	2973	3080	3183	1666	2482	2681	2547	2433	2057	5822	2301	2555	4110	2396	3264	4864	2298	2411	2145	2621	2730	3252	3506	3680	2279	2233	1841	1587	3620	1875	2571	3111	1652	2662	1293	1031	2558	4459	3643	2566	3521	3076	3336	2707	3656	5483	3128	1629	3909	2570	2850	4349	3398	1547	2255	2515	3193	5015	3333	4084	2892	2871	4666	4855	2565	2487	2426	4009	5169	3215	4943	1553	2213	1836	1447	2028	2522	3780	2452	1869	1552	2140	14244	2467	1729	3664	2864	4120	3017	2667	2357	1471	1435	1149	1801	2743	1842	3049	5126	2561	1568	1692	2886	2840	4274	7888	2936	2446	2569	1909	2475	1674	2187	1690	2031	3347	4322	1341	2088	2635	1794	2273	2417	1426	1611	1449	1653	5291	3094	2544	2732	1319	2617	8705	15564	2783	0	2062	2407	2388	2387	1392	3475	2164	3448	1979	2891	3837
LPC 18:0	967088875	1743532875	268820875	326680875	195564875	228136875	283458875	246380875	351169875	218355875	216508875	222663875	406638875	244949875	295473875	289167875	289744875	233043875	211724875	249295875	422895875	363441875	338955875	457073875	322898875	345691875	337341875	248754875	327038875	511105875	205147875	246222875	238807875	177182875	290435875	318184875	341659875	554874875	279806875	294009875	220125875	265720875	472376875	190605875	252796875	331951875	297926875	172999875	329245875	338634875	213040875	362690875	306775875	363982875	240762875	266894875	267687875	261248875	367747875	521625875	415436875	307557875	446048875	203213875	188144875	437891875	476650875	270453875	315568875	271490875	351845875	520646875	397870875	403632875	433623875	332443875	468806875	405362875	247145875	230327875	216510875	437891875	464161875	339957875	475274875	181879875	217532875	145596875	236110875	282809875	261222875	478482875	296959875	192539875	239040875	296312875	1621333875	251378875	258829875	324466875	230151875	356209875	304438875	244330875	219824875	161872875	210263875	156250875	248250875	185799875	152939875	273706875	335099875	334546875	188762875	179023875	243292875	309475875	488160875	898751875	372678875	307140875	399436875	242039875	275776875	288641875	254720875	269262875	272123875	410346875	317557875	176501875	259504875	311502875	212750875	242787875	243597875	169505875	215274875	233396875	228605875	345893875	302042875	275100875	187644875	187129875	292602875	922335875	1681077875	263886875	-1179125	201488875	219098875	361832875	327207875	191885875	367821875	189634875	343724875	322658875	204594875	276001875
LPC 18:1	812775	1418445	201272	194907	132513	169194	190186	144500	225804	162796	162507	163359	336023	169254	253894	183085	153598	143556	150841	241127	203679	189895	164522	342585	218605	245980	296827	189009	257398	416813	131295	221153	255195	135547	224980	264035	251648	259579	157612	146450	121718	113783	271000	133732	183739	219708	171706	198084	239895	183567	156864	247980	257117	244055	322616	247809	254407	208682	291469	458799	308422	250275	372484	233781	230770	304842	322079	138275	184042	200077	275304	435911	223569	261380	242331	219680	328883	282406	171278	192767	218655	325817	402854	224417	350135	124957	161018	140239	131371	170141	219144	295044	165871	116704	109361	139561	1268951	183449	112648	203197	228389	388624	224158	207099	166110	128842	130243	102754	145175	186727	150804	230855	306556	290258	165449	214853	181011	237744	371681	696610	285029	261047	228515	162449	175025	159827	142469	117606	151804	277487	237868	119232	158445	253721	181730	172620	173218	111879	119990	100382	138970	267077	287545	184820	153369	148590	230780	767029	1378696	197573	0	159407	158806	211434	177223	96246	202715	134669	194443	141623	171063	222112
LPC 19:0	3089125	5535125	656125	62125	637125	654125	741125	728125	789125	79125	-6875	-15875	37125	50125	55125	-14875	27125	75125	-4875	60125	65125	21125	52125	72125	17125	15125	8125	762125	1011125	1659125	47125	-12875	-4875	54125	31125	110125	77125	-4875	55125	33125	-5875	521125	695125	540125	756125	-4875	0125	-4875	50125	22125	29125	7125	-6875	7125	-10875	-13875	37125	585125	1135125	1552125	-16875	39125	90125	28125	29125	114125	23125	5125	11125	734125	951125	1564125	26125	80125	-9875	64125	78125	38125	6125	34125	1125	52125	-6875	68125	70125	801125	730125	12125	-1875	15125	1125	39125	67125	-5875	85125	24125	5981125	685125	-4875	1039125	769125	1122125	24125	73125	16125	37125	21125	-8875	-2875	22125	63125	-1875	21125	25125	9125	-17875	56125	1084125	1810125	3290125	64125	113125	9125	73125	5125	-3875	7125	40125	72125	9125	36125	138125	42125	-2875	112125	-15875	52125	540125	5125	13125	38125	35125	-10875	25125	41125	1125	51125	2967125	6433125	843125	-19875	415125	360125	47125	21125	-17875	14125	-10875	51125	522125	699125	854125
LPE 18:0	19343	30901	5538	6060	4462	5375	6160	5221	7283	5092	5238	5256	8534	5077	5610	7525	7247	4910	4881	6369	8559	5497	5074	10513	9571	9953	9021	5324	7426	10266	4978	6004	5312	6883	6035	6724	9372	13254	6209	5950	5531	5404	9250	4650	5670	5105	4177	4783	3405	5002	6019	8116	7097	8588	7612	6558	8167	6189	8492	11491	8928	6251	7479	6358	5588	11577	9600	6143	6300	5873	7306	11434	7949	7284	9716	6506	9440	7991	4981	4885	4959	9925	9618	6898	8328	3941	4979	4348	6537	6289	5515	7645	4463	2432	2704	8958	27382	5154	8119	6614	6604	8475	7840	5211	4464	5036	5196	2862	5772	5267	4522	7240	8358	7872	4524	5104	9427	6682	9326	16767	5467	4329	7317	5687	7666	4812	4608	3888	4510	7701	5589	4860	6145	7828	5143	5051	5250	3570	3837	3437	5124	6672	5071	7085	4117	3790	6299	17625	28953	5449	-7	4965	5588	8133	7822	2764	10729	4844	8128	5625	5421	7537
LPI 20:4	625	1012	163	224	112	102	163	225	252	346	236	271	253	183	183	211	347	122	98	158	260	258	313	306	142	176	181	184	241	358	120	167	66	292	234	214	266	98	159	163	160	176	322	137	166	216	183	266	260	203	214	298	291	275	371	330	356	128	215	248	292	261	227	302	173	89	213	109	235	142	179	361	250	267	170	242	170	76	216	144	152	228	197	260	152	134	154	125	156	177	138	287	223	225	264	241	1523	214	391	193	135	243	110	147	175	152	217	285	92	172	149	269	183	225	163	135	149	368	528	894	244	235	254	245	150	163	286	267	295	173	194	180	293	301	274	241	273	227	270	288	215	90	149	252	184	159	131	643	1151	155	0	369	425	265	227	322	394	595	157	134	106	83
Palmitoleic acid	4755525	7665425	2472125	580925	1434925	1687925	1135225	3320025	1433925	1814925	1861225	1869825	674325	2545825	1212325	328525	520025	4861525	5677125	820525	5492125	1883025	928825	1227725	987025	915725	414125	1684825	2133625	2761825	1284025	2897825	4851825	369125	376225	401925	496925	1096925	1010925	1596625	6534425	5155625	4247325	1451525	1674625	2282025	409125	909725	1075225	564825	3938925	623225	2419625	9041525	1182325	1358525	437725	1796325	2358425	3097825	610025	2007625	2280325	883625	1119725	290625	2713025	2680325	2441125	1713625	2309025	2901425	1695925	2487125	1303125	1014625	2039525	482825	977125	3142225	7747625	457725	1128825	4299925	1004525	1352725	1551825	2872125	2685125	875125	201725	1292125	1006925	4448725	1467025	1430125	7104125	2209025	4752325	1695625	1182125	843925	545025	590625	868625	2857925	2966125	5508925	2333125	1693425	1594325	1596525	803925	1227425	188025	215825	1289025	2028825	2607225	4214325	2084925	1621525	996925	1093025	402525	3067125	583925	9938425	1624525	255025	589025	1213225	5083625	1392425	7124425	2006625	2094925	1169325	293625	2109625	6045125	950625	1464825	1011425	5910225	1162825	661625	4435125	7336225	2387425	-202375	1737825	1767725	2357425	429825	5073625	2962125	1404325	390625	563925	1559925	1745525
Lauric acid	7822625	14154625	1038625	808625	2155625	1573625	1216625	1069625	185625	599625	598625	557625	561625	1365625	363625	127625	827625	3819625	2070625	667625	1896625	2279625	449625	542625	356625	628625	524625	1986625	2447625	3925625	378625	2461625	2255625	470625	241625	463625	617625	327625	895625	1359625	2507625	2131625	372625	1384625	1693625	483625	299625	759625	548625	342625	2658625	242625	717625	2786625	491625	376625	358625	2074625	2918625	4818625	1322625	708625	2435625	842625	2277625	997625	1660625	953625	1404625	2136625	3071625	4039625	655625	793625	11522625	1465625	1826625	375625	672625	999625	1592625	251625	420625	1302625	239625	996625	1463625	1794625	534625	351625	247625	1212625	903625	516625	71625	415625	13288625	611625	1239625	296625	1689625	965625	522625	49625	361625	971625	773625	1566625	747625	5616625	479625	1312625	991625	1300625	532625	-22375	149625	2174625	3624625	7240625	1270625	587625	5246625	659625	485625	1709625	246625	797625	1086625	37625	1186625	1524625	2665625	560625	1301625	564625	615625	859625	520625	540625	794625	1465625	988625	513625	3472625	277625	271625	7345625	12937625	827625	-633375	400625	407625	1486625	540625	1387625	880625	291625	610625	907625	1287625	1266625
Arachidonic acid	52233875	82395875	20771875	17842875	15606875	17792875	22194875	28170875	22925875	15731875	16016875	15967875	11796875	28638875	28616875	20213875	21611875	31604875	31888875	15122875	33226875	24346875	32454875	31227875	13709875	10746875	24012875	18356875	22490875	31739875	12826875	20990875	16643875	23753875	17918875	17408875	11057875	18707875	16520875	40903875	34729875	28482875	48993875	15900875	18485875	21736875	18782875	23403875	19920875	18926875	23590875	17620875	17502875	34837875	16986875	18067875	14263875	20197875	25473875	34022875	40396875	25063875	41047875	20608875	23596875	17096875	36284875	21393875	21298875	19250875	24196875	31937875	23810875	23673875	23626875	24387875	35735875	12368875	27263875	15135875	27576875	19715875	19607875	33567875	18222875	14701875	17119875	20472875	31983875	21035875	25699875	33211875	25955875	24486875	21904875	45069875	79374875	18898875	37807875	20873875	32639875	36729875	29304875	18112875	36447875	34822875	22993875	33759875	23479875	36678875	17132875	18582875	10808875	45079875	10505875	13435875	16243875	20935875	29580875	47714875	27885875	14496875	29343875	12785875	13434875	24243875	21698875	39155875	23563875	19974875	24197875	22501875	35308875	21223875	51728875	17313875	17939875	12183875	13395875	20656875	38608875	25008875	13977875	14154875	40543875	16253875	24258875	50256875	82825875	20247875	316875	15530875	15490875	39668875	18037875	34473875	25025875	17784875	38153875	19898875	19545875	17221875
Oleic acid	596837125	860125125	268164125	170457125	185831125	216172125	243657125	409130125	226790125	263741125	267316125	258360125	127968125	322280125	151820125	81094125	91933125	510518125	499938125	92297125	587227125	298489125	155849125	137612125	142753125	161258125	67965125	233937125	292225125	384079125	225419125	366595125	456443125	78514125	111627125	87415125	81133125	214328125	232697125	230764125	496120125	474003125	392521125	180012125	217952125	250207125	132493125	182567125	257213125	196020125	423897125	87636125	331430125	635544125	219314125	276385125	71114125	233908125	300489125	395398125	162598125	435032125	406886125	199228125	187058125	61124125	292049125	300584125	276051125	238457125	293873125	397780125	236934125	370265125	391407125	286073125	217018125	63614125	166707125	271800125	493992125	115159125	182586125	513153125	133719125	182703125	213328125	374717125	206962125	116195125	58299125	359370125	213180125	421957125	154711125	84424125	930705125	272893125	582679125	241420125	228085125	251239125	121289125	157091125	150390125	449999125	394160125	580940125	275852125	300116125	279107125	259474125	121484125	158516125	61575125	119244125	176967125	297850125	401507125	616400125	317834125	320861125	190267125	154967125	84214125	274561125	139046125	573497125	235170125	67736125	183714125	294510125	484729125	209664125	696052125	272711125	272620125	178408125	68475125	248137125	572003125	172454125	290305125	152486125	673383125	189248125	137208125	590181125	871576125	266173125	-11429875	252353125	254206125	384131125	166237125	433147125	413237125	255254125	79355125	122252125	257026125	184982125
Bilirubin	975	1122	283	272	282	395	802	987	967	1095	703	659	455	654	859	402	1050	166	670	569	172	418	733	366	624	708	638	382	394	582	210	591	351	344	1339	1048	505	256	379	242	1195	747	367	263	332	405	722	538	813	936	450	825	834	141	454	394	426	322	429	576	452	567	611	409	826	1423	121	919	366	257	400	555	2560	1867	222	534	276	668	703	323	621	173	322	814	736	365	327	206	190	675	1041	321	894	366	367	227	1698	416	234	2395	2647	2151	1228	1559	1751	400	513	1426	180	172	739	356	473	600	964	498	548	739	787	1328	1343	357	465	378	289	239	1190	351	993	1102	557	153	627	787	428	536	577	510	1704	1587	830	478	491	351	355	1313	1369	772	1251	230	0	1421	1145	537	485	931	534	1026	690	241	455	601
Oleamide	3201125	7884125	-1040875	-927875	-920875	-626875	-897875	-1022875	-1121875	-148875	-259875	-63875	-853875	-1088875	-1128875	-1094875	-739875	-965875	-574875	-1061875	-810875	-938875	-799875	-847875	-1092875	-907875	-843875	-1014875	-271875	1041125	-894875	-1121875	-944875	-556875	-741875	-779875	-820875	-835875	-985875	-1088875	-1058875	-739875	-1060875	-775875	-465875	-890875	-1116875	-1076875	-879875	-913875	-1132875	-785875	-828875	-1229875	-1020875	-1012875	-1116875	-809875	-216875	949125	-1073875	-933875	-839875	-970875	-1036875	-1078875	-912875	-974875	-1101875	-781875	-93875	943125	-703875	-655875	-948875	-980875	-1434875	-1224875	-1027875	-976875	-1031875	-920875	-1156875	-1027875	-1064875	-1241875	-727875	-1035875	-1023875	-1199875	-1040875	-1131875	-964875	-876875	-1050875	-1134875	8876125	-602875	-832875	-1191875	-606875	-866875	-980875	-994875	-1346875	-1026875	-790875	-1204875	-1092875	-976875	-1249875	-908875	-857875	-1112875	-945875	-876875	-1141875	308125	2027125	3940125	-887875	-1057875	-690875	-834875	-1199875	-1092875	-784875	-354875	-1127875	-1172875	-1006875	-811875	-913875	-937875	-1157875	-568875	-669875	-720875	-708875	-955875	-1126875	-887875	-861875	-941875	-1062875	-1149875	-922875	3425125	7311125	-894875	-200875	-103875	-69875	-978875	-999875	-942875	-806875	-740875	-637875	-906875	-969875	-930875
Lactic acid	144296375	196952375	22648375	44890375	72902375	76969375	41084375	35616375	40265375	29458375	28658375	28394375	56917375	38359375	41062375	84666375	86757375	29824375	55423375	55639375	25985375	57454375	61854375	56122375	50211375	68792375	59164375	75588375	83536375	102666375	105883375	42164375	36635375	29018375	22656375	49464375	56053375	96568375	48681375	62190375	67933375	51446375	40614375	78088375	84438375	31957375	49394375	42285375	24356375	42045375	39817375	35758375	40553375	28035375	52576375	64938375	117413375	87036375	98383375	118628375	33485375	18664375	36151375	51494375	47133375	40895375	73680375	54017375	70243375	81164375	90505375	108428375	64419375	69079375	24742375	78296375	51962375	35276375	48331375	29393375	52449375	64187375	61054375	31648375	86751375	67908375	71785375	38260375	36257375	22533375	59957375	71551375	69056375	34269375	41822375	68418375	175842375	26099375	85978375	21806375	57917375	54790375	34094375	24260375	31428375	28722375	26737375	62364375	41894375	69816375	52048375	45735375	41710375	48145375	31450375	72309375	75623375	89430375	105153375	132268375	41380375	30450375	73156375	55827375	40797375	32782375	74721375	39843375	70333375	41953375	49337375	28316375	43978375	64237375	48848375	29324375	29559375	77036375	47164375	57656375	24271375	32132375	47902375	47280375	71072375	63036375	52206375	134591375	184301375	22604375	-232625	26796375	28802375	28749375	36802375	25287375	66292375	52621375	51336375	59422375	33408375	30757375
Pyruvic acid	1472	2369	716	511	597	676	700	549	572	1631	1590	1543	981	569	612	1778	1973	759	683	633	518	743	607	1276	1162	1059	942	723	795	1003	1353	453	522	673	645	898	918	1580	1044	511	1146	974	827	662	650	1215	1273	1096	440	881	951	778	1259	636	1296	1200	1861	672	803	1019	616	451	673	1209	1206	695	491	1662	1195	733	792	1013	924	925	632	1704	356	863	598	558	679	926	759	646	1417	648	669	566	265	297	969	1341	1451	504	906	411	3292	1113	2012	524	1007	1051	509	454	411	755	620	981	438	433	1222	933	1310	570	715	828	1236	1169	1484	2097	903	497	1007	1538	1038	892	1661	658	1024	979	1076	724	757	1323	952	1409	1383	1026	1623	804	691	720	896	1325	1438	637	828	1483	2452	731	0	1727	1662	515	1198	638	2700	1573	399	848	476	560
Sphingosine d7	947074	988434	1015364	936819	905407	950256	961481	1020198	971623	800113	795881	791000	913838	916830	866244	905149	918133	892010	938320	906270	916063	891600	885090	884487	962788	982468	1001038	948519	883380	916385	959080	924153	973027	833473	816027	843302	1199799	945502	952152	917754	970024	949447	949391	953398	903466	906309	916952	842021	886675	915519	942389	877455	854765	872882	950052	955743	962796	936346	958972	913631	962281	952964	930748	943825	955100	930817	902403	909961	915137	982559	977769	970155	849269	891862	878319	919851	889515	900934	913161	1007672	989609	839624	835782	833692	894156	936848	880536	917843	906355	895566	896161	887545	942804	945967	925674	901315	820291	823435	820595	947339	948226	955861	916080	912582	912984	826592	818985	827136	898639	935287	913800	934635	991288	925752	963461	978551	984916	823955	807827	829738	877585	961594	889125	928561	954724	965443	870027	937431	923214	840092	852014	841196	886364	846743	857238	800669	804845	805892	832764	830050	839692	907227	942124	960911	925373	922718	876726	900430	921075	914816	787868	780078	808223	836186	838045	822331	820750	828611	824834	943716	948199	918679
LPC 18:1 d7	180894	191120	195740	179140	178781	179438	172214	185373	177292	156321	158121	147885	180792	177171	167647	178252	177344	174119	170042	169794	167079	170703	170224	171427	188006	187081	190748	182934	173831	176425	180753	174288	179008	164148	160892	161471	227681	178099	174149	171359	181489	173632	171309	179825	156956	177691	176990	162124	174669	176139	182703	176592	168682	170722	186552	184214	188164	177080	174846	166732	189487	186147	186305	184703	188201	183328	161278	168840	171927	192251	197332	188058	171968	175484	175107	176846	170350	172722	170808	185269	186653	166148	168065	160402	173019	180539	168772	168530	167155	165186	172332	169972	180446	187767	186463	177225	163057	162407	158180	173895	175345	173214	176980	173779	179143	160706	162777	160253	166247	172880	170256	171628	191090	181477	189384	191220	186688	160284	156157	164588	170801	194523	175428	179126	186439	188861	172958	184143	183322	164107	164478	164571	173965	170845	166869	160111	156581	159751	163391	165488	160775	177970	179644	193129	168258	169400	165731	173112	176720	185492	151561	148741	155942	166227	157849	161982	157271	160530	155634	171776	173840	172715
Palmitic acid d31	30951	30575	32235	31278	30739	31670	34885	36772	34115	30646	31354	29790	30278	30915	28210	31673	31436	28974	35418	32169	33954	31146	28058	29339	31798	33526	31653	30715	29869	30965	35221	34030	34359	30652	28599	29696	43044	35620	33341	33990	35223	35767	33749	34894	32266	30252	31482	29021	30149	30834	31294	30144	28848	29652	30333	32475	30797	33463	35929	31640	33053	32899	31946	33321	33712	32188	33013	35006	33620	31750	32310	30786	31837	31890	31022	30591	29771	30547	33486	38068	36934	30248	30453	29737	29401	32028	29216	33904	33433	33091	30639	30596	31348	32811	31435	30587	30231	31562	30725	35475	36446	34907	31212	31554	31377	29970	30004	29733	34036	34129	33616	31320	33112	31738	32359	32525	32720	30536	31514	31203	30324	33440	30941	30545	33122	33841	30457	32427	32719	30478	31625	30290	30797	30812	30587	31011	31261	31128	30671	29839	31338	29781	32437	32073	32929	34739	32582	29564	31487	30590	28357	28261	29709	31122	30394	29399	30986	29952	29594	34953	36000	34056
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	PubChem ID
Sphingosine	5280335
Sphingosine-1-Phosphate	5283560
LPC 14:0	460604
LPC 16:0	460602
LPC 17:0	24779463
LPC 17:1	42607442
LPC 18:0	497299
LPC 18:1	24779492/24779493/24779494/24779465
LPC 19:0	24779472
LPE 18:0	53480667
LPI 20:4	138124432
Palmitoleic acid	445638
Lauric acid	3893
Arachidonic acid	444899
Oleic acid	445639
Bilirubin	5280352
Oleamide	5283387
Lactic acid	612
Pyruvic acid	1060
Sphingosine d7	129856538  
LPC 18:1 d7	164484290
Palmitic acid d31	16212358
METABOLITES_END
#END